Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer.
Status:
Active, not recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The aim of this prospective, randomized, multicenter, open-label, phase II study is to test
if chemotherapy can be replaced by the combination of ribociclib plus letrozole as a
neo-adjuvant therapy for patients with non-metastatic primary luminal breast cancer.